Abstract
Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy. One important mechanism of MDR involves the multidrug transporter, P-glycoprotein (Pgp), which confers upon cancer cells the ability to resist lethal doses of certain cytotoxic drugs by pumping the drugs out of the cells and thus reducing their cytotoxicity. Pgp belongs to the ATP-binding cassette (ABC) family of transporter molecules which require hydrolysis of ATP to run the transport mechanism. The substrates of Pgp may be endogenous (steroid hormones, cytokines) or exogenous (cytostatic drugs). A number of studies have demonstrated a negative correlation between Pgp expression levels and chemosensitivity or survival in a range of human malignancies. In principle, Pgp mediated drug resistance can be circumvented by treatment regimens that either exclude Pgp substrate drugs or include Pgp inhibitory agents. Experimental studies have demonstrated that certain structural modifications of anthracyclines confer t he ability to escape Pgp transport. The therapeutic benefit of Pgp inhibitors as chemosensitizers is currently being explored in phase III clinical trials, and the first promising results have already been reported. Another therapeutic option for Pgp inhibitors has recently evolved as several Pgp inhibitors, many of which are generally low-toxic substances, by themselves constrain proliferation and cause cell death by apoptosis in certain MDR cancer cell lines. The dual effect of Pgp inhibitors, targeting MDR cancer cells selectively, may translate into improved efficacy of cancer chemotherapy and perhaps new and less toxic drug treatment strategies in human MDR cancer.
Keywords: Cancer, Glycoprotein, Cytokines, Cytostatic drugs, ATP binding cassette ABC, Steroid Hormones, Drug Target, cMOAT, Multidrug Transprot, Cortisol
Current Drug Targets
Title: P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer
Volume: 1 Issue: 1
Author(s): Gustav Lehne
Affiliation:
Keywords: Cancer, Glycoprotein, Cytokines, Cytostatic drugs, ATP binding cassette ABC, Steroid Hormones, Drug Target, cMOAT, Multidrug Transprot, Cortisol
Abstract: Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy. One important mechanism of MDR involves the multidrug transporter, P-glycoprotein (Pgp), which confers upon cancer cells the ability to resist lethal doses of certain cytotoxic drugs by pumping the drugs out of the cells and thus reducing their cytotoxicity. Pgp belongs to the ATP-binding cassette (ABC) family of transporter molecules which require hydrolysis of ATP to run the transport mechanism. The substrates of Pgp may be endogenous (steroid hormones, cytokines) or exogenous (cytostatic drugs). A number of studies have demonstrated a negative correlation between Pgp expression levels and chemosensitivity or survival in a range of human malignancies. In principle, Pgp mediated drug resistance can be circumvented by treatment regimens that either exclude Pgp substrate drugs or include Pgp inhibitory agents. Experimental studies have demonstrated that certain structural modifications of anthracyclines confer t he ability to escape Pgp transport. The therapeutic benefit of Pgp inhibitors as chemosensitizers is currently being explored in phase III clinical trials, and the first promising results have already been reported. Another therapeutic option for Pgp inhibitors has recently evolved as several Pgp inhibitors, many of which are generally low-toxic substances, by themselves constrain proliferation and cause cell death by apoptosis in certain MDR cancer cell lines. The dual effect of Pgp inhibitors, targeting MDR cancer cells selectively, may translate into improved efficacy of cancer chemotherapy and perhaps new and less toxic drug treatment strategies in human MDR cancer.
Export Options
About this article
Cite this article as:
Lehne Gustav, P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer, Current Drug Targets 2000; 1 (1) . https://dx.doi.org/10.2174/1389450003349443
DOI https://dx.doi.org/10.2174/1389450003349443 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders Relevance of Dopamine D2/Neurotensin NTS1 and NMDA/Neurotensin NTS1 Receptor Interaction in Psychiatric and Neurodegenerative Disorders
Current Medicinal Chemistry Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Calcium Channel Subtypes and Exocytosis in Chromaffin Cells at Early Life
Current Molecular Pharmacology Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Current Alzheimer Research Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Natural Bioactives as Potential Therapeutic Modalities Against NeuroAIDS
Current Topics in Medicinal Chemistry To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine Histopathology Image Analysis and Classification Using ARMA Models: Application to Brain Cancer Detection
Current Medical Imaging Flavonoids Protect Cerebrovascular Endothelial Cells through Nrf2 and PI3K from β-Amyloid Peptide-Induced Oxidative Damage
Current Neurovascular Research Editorial (Thematic Issue: Novel Pharmaceutical Approaches by Natural Compound-Derived Epigenetic Regulators: Epigenetic Readers, Writers and Erasers as Therapeutic Targets)
Current Topics in Medicinal Chemistry Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Quality, not Quantity: The Role of Natural Products and Chemical Proteomics in Modern Drug Discovery
Combinatorial Chemistry & High Throughput Screening Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Estrogens and Thyroid Hormones: Non-Genomic Effects are Coupled to Transcription
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Signal Transduction via Cannabinoid Receptors
CNS & Neurological Disorders - Drug Targets